Herpes Simplex Keratitis Treatment Market

Herpes Simplex Keratitis Treatment Market Overview

The global herpes simplex keratitis treatment market size is anticipated to reach US$ 4.2 Billion in 2022. It is expected to be valued at US$ 7.9 Billion in 2032 and exhibit growth at a robust CAGR of 6.1% in the forecast period from 2022 to 2032. The ongoing development of advanced healthcare infrastructures worldwide is likely to augment the demand for herpes simplex keratitis treatment in the assessment period.

Herpes simplex virus keratitis is an infection of epithelial cells that are present on the surface of the eye. It also causes the retrograde infection of nerves that serve the cornea.

Primary infection usually leads to the swelling of eyelids and the conjunctiva, as well as itchy, white lesions on the corneal surface. Some of the additional symptoms include sinusitis, mild to acute dryness, and dull pain in the eye.

Recurrent infection is often caused by reactivation of the virus and transportation of the same from the nerve axon to sensory nerve endings. Antiviral treatment either in the form of topical medications or oral administration of famciclovir or valacyclovir for 10-14 days is required when keratitis occurs.

The condition is diagnosed by a slit-lamp examination. The rising adoption of topical therapy owing to its high efficacy is anticipated to propel the market in the future years.

Which are Some Prominent Drivers Spearheading Herpes Simplex Keratitis Treatment Market Growth?

The increasing research and development activities conducted by numerous key players to launch new drugs is set to propel the market in the near future. The rising cases of herpes simplex virus type 2 and herpes simplex virus type 1 across the globe is another major factor that is estimated to bode well for the herpes simplex keratitis treatment market growth.

According to the World Health Organization (WHO), nearly 3.7 billion people under the age of 50 years have herpes simplex virus type 1 infection across the globe, whereas around 491 million people aged 15 to 49 years have herpes simplex virus type 2 infection. These numbers are set to surge in the upcoming years, thereby propelling the growth in this market.

What are the Challenges Faced by the Herpes Simplex Keratitis Treatment Industry?

The cost of herpes simplex keratitis treatment is very high. As per a study conducted by a team of researchers at the Saint Louis University, Missouri, people in the U.S. spend tens of millions for the treatment of this condition. People, especially in emerging economies may not be able to spend a huge amount and this may hamper the herpes simplex keratitis treatment market growth in future.

Why is North America emerging as an Opportunistic Herpes Simplex Keratitis Treatment Market?

North America is projected to remain at the forefront by procuring the largest herpes simplex keratitis treatment market share in the near future. The increasing prevalence of infections associated with the herpes simplex virus in the U.S. is a leading factor that is likely to propel the market. Sexually active individuals or those who have had 3 or more sex partners in their lifetime are at a high risk of developing type 1 keratitis.

According to the Centers for Disease Control and Prevention (CDC), 1 in 5 individuals have a Sexually Transmitted Infection (STI), such as genital herpes in the U.S., totaling around 68 million infections in 2018. In addition to that, new STIs total approximately US$ 16 billion in direct medical costs. This trend is projected to continue throughout the evaluation period, thereby boosting the North America market.   

How is Asia Pacific Contributing to Growth of the Herpes Simplex Keratitis Treatment Market?

The growing number of new product launches by reputed companies is expected to fuel the sales of herpes simplex keratitis treatment options in Asia Pacific. The surging number of clinical trials in China, Singapore, and Malaysia is another significant factor that is estimated to augur well for the market.

In June 2021, for instance, a hospital in Ghaziabad, India, reported the first-ever case of herpes simplex virus infection that was termed as ‘very dangerous.’ Doctors discovered that COVID-19 recovered patients who have a weak immune system are most likely to develop this condition. Thus, the rising incidence of life-threatening disorders across Asia Pacific is projected to accelerate the market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Market Competition

The global herpes simplex keratitis treatment market contains a large number of big and small players. Some of them include Aurobindo Pharma, GlaxoSmithKline, Cipla, Blistex, Mylan, Vectans Pharma, Dr. Reddy's Laboratories, Bausch Health, and Jubilant Cadista among others.

Majority of the leading companies are increasingly focusing on mergers and acquisitions, as well as geographical expansions to gain a competitive edge in the market. Meanwhile, a few other key players are striving to come up with innovative products to fulfill the high unmet needs of patients across the globe.

Scope of Report 

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Key Segments Profiled in the Herpes Simplex Keratitis Treatment Industry Survey

By Drug:

• Famciclovir
• Valacyclovir
• Acyclovir
• Other Drugs

By Route of Administration:

• Topical
• Injection
• Oral

By Region:

• North America
• Latin America
• Western Europe
• Easter Europe
• APEJ
• Japan
• Middle East & Africa